Business
AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function
PRESS RELEASE AB SCIENCE ANNOUNCES NEW PUBLICATION ON MEDRXIV HIGHLIGHTING CLINICAL BENEFIT WITH MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS PATIENTS PRIOR ANY COMPLETE LOSS OF FUNCTION Significant improvement in functional decline measured by the ALSFRS-R score, with a 4.04-point difference favoring masitinib over placebo (p=0.0065)Significant benefit on CAFS (relative benefit +20.2%, p=0.0290)Median progression-free survival (PFS) extended by 9 months (p=0.0057)Median overall survival (OS) incr
About this update from Ab Science Sa
[{"type":"image","alt":"AB Science","displaySize":"","headline":null,"caption":"AB Science","className":"","disableSlideshowImg":false,"size":{"original":{"width":156,"height":160,"url":"https://media.zenfs.com/en/globenewswire.com/7964f89fed41da51df043a8d3708bbe2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AW2UM4sIueJ.X0XSJNjHhQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7964f89fed41da51df043a8d3708bbe2","width":156,"height":160}},"lazy":false},{"type":"text","content":"PRESS RELEASE","length":13,"tagName":"p"},{"type":"text","content":"AB SCIENCE ANNOUNCES NEW PUBLICATION ON MEDRXIV HIGHLIGHTING CLINICAL BENEFIT WITH MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS PATIENTS PRIOR ANY COMPLETE LOSS OF FUNCTION","length":170,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Significant improvement in functional decline measured by the ALSFRS-R score, with a 4.04-point difference favoring masitinib over placebo (p=0.0065)","length":149,"tagName":"p"}]},{"val":[{"type":"text","content":"Significant benefit on CAFS (relative benefit +20.2%, p=0.0290)","length":63,"tagName":"p"}]},{"val":[{"type":"text","content":"Median progression-free survival (PFS) extended by 9 months (p=0.0057)","length":70,"tagName":"p"}]},{"val":[{"type":"text","content":"Median overall survival (OS) increased by 12 months (p=0.0192)","length":62,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":344,"olType":false},{"type":"text","content":"THESE RESULTS INFORMED THE DESIGN OF CONFIRMATORY STUDY AB23005, TARGETING PATIENTS PRIOR ANY COMPLETE LOSS OF FUNCTION TO OPTIMIZE THE BENEFIT-RISK BALANCE AND ENHANCE THE LIKELIHOOD OF STUDY SUCCESS ","length":200,"tagName":"p"},{"type":"text","content":"Paris, December 11, 2025, 6.30pm CET","length":36,"tagName":"p"},{"type":"text","content":"AB Science SA (Euronext - FR0010557264 - AB) today announced the publication of a new article on the preprint platform MedRxiv, presenting a post-hoc subgroup analysis of the phase 2b/3 AB10015 study evaluating masitinib in patients with amyotrophic lateral sclerosis (ALS). This article is entitled ‘Efficacy and safety of masitinib in amyotrophic lateral sclerosis patients prior to loss of functionality: a subgroup analysis optimizing the benefit-risk profile of masitinib’ and is freely accessible online from the med...